{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:50:40Z","timestamp":1791957040026,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.amjmed.2023.10.022","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:39:40Z","timestamp":1698727180000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2920-7673","authenticated-orcid":false,"given":"Jiayi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar Stef\u00e1n","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269216318807051","article-title":"Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis","volume":"33","author":"Peng","year":"2019","journal-title":"Palliat Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.022_bib0002","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cld.711","article-title":"Pain management in patients with cirrhosis","volume":"11","author":"Rakoski","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.022_bib0003","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0006-2952(94)90524-X","article-title":"Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics","volume":"47","author":"Girre","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.022_bib0004","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/gut.29.9.1153","article-title":"Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity","volume":"29","author":"Lauterburg","year":"1988","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.022_bib0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.1840220312","article-title":"Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure","volume":"22","author":"Zimmerman","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.022_bib0006","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2036.2010.04364.x","article-title":"The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study","volume":"32","author":"Dart","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1741-7015-5-13","article-title":"The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients\u2013a multicenter randomized study","volume":"5","author":"Kuffner","year":"2007","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/clpt.1983.14","article-title":"Acetaminophen in chronic liver disease","volume":"33","author":"Benson","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.0954-6820.1979.tb00728.x","article-title":"Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver","volume":"624","author":"Andreasen","year":"1979","journal-title":"Acta Med Scand Suppl"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep4.1810","article-title":"Short-term safety of repeated acetaminophen use in patients with compensated cirrhosis","volume":"6","author":"McGill","year":"2022","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.022_bib0011","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cgh.2009.04.015","article-title":"Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis","volume":"7","author":"Khalid","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.022_bib0012","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3109\/00365521003663704","article-title":"Over-the-counter analgesics in cirrhotic patients: a case-control study examining the risk of hospitalization for liver-associated events","volume":"45","author":"Fenkel","year":"2010","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.022_bib0013","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2165\/11635500-000000000-00000","article-title":"Analgesics in patients with hepatic impairment: pharmacology and clinical implications","volume":"72","author":"Bosilkovska","year":"2012","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.amjmed.2023.10.022_bib0014","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1111\/j.1572-0241.2002.05847.x","article-title":"Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study","volume":"97","author":"Ackerman","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.022_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.20595","article-title":"Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites","volume":"41","author":"Cl\u00e0ria","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.44.2.270","article-title":"Anti-inflammatory drugs and variceal bleeding: a case-control study","volume":"44","author":"De L\u00e9dinghen","year":"1999","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.022_bib0017","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1478-3231.2011.02739.x","article-title":"Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients","volume":"32","author":"Lee","year":"2012","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.022_bib0018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2012.05225.x","article-title":"Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study","volume":"36","author":"Luo","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.amjmed.2023.10.022_bib0019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/11533350-000000000-00000","article-title":"Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis","volume":"30","author":"Jones","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.022_bib0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/00365520310008205","article-title":"Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study","volume":"39","author":"Guevara","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0021","unstructured":"Food and Drug Administration (FDA). Celebrex. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020998s026lbl.pdf. Accessed November 5, 2023."},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjopharm.2011.12.002","article-title":"Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities","volume":"10","author":"Baraf","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0023","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0091270009336234","article-title":"Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers","volume":"50","author":"Kienzler","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0024","unstructured":"LiverTox. Opioids. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547864\/#top. Accessed November 5, 2023."},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.022_bib0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4065\/mcp.2009.0534","article-title":"Pain management in the cirrhotic patient: the clinical challenge","volume":"85","author":"Chandok","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.022_bib0026","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/hep.30336","article-title":"Frailty, psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis","volume":"69","author":"Tapper","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/apt.13858","article-title":"Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis","volume":"45","author":"Acharya","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.022_bib0028","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep4.1694","article-title":"Patterns of inpatient opioid use and related adverse events among patients with cirrhosis: a propensity-matched analysis","volume":"5","author":"Rubin","year":"2021","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229497","article-title":"In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge","volume":"15","author":"Moon","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.amjmed.2023.10.022_bib0030","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/hep4.1425","article-title":"Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis","volume":"3","author":"Tapper","year":"2019","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.022_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/apt.15639","article-title":"Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis","volume":"51","author":"Moon","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"4 suppl","key":"10.1016\/j.amjmed.2023.10.022_bib0032","doi-asserted-by":"crossref","first-page":"A661","DOI":"10.1016\/j.chest.2020.08.621","article-title":"Chronic opioid use is independently associated with prolonged mechanical ventilation in critically ill patients with cirrhosis","volume":"158","author":"Glick","year":"2020","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.022_bib0033","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2044.1992.tb02166.x","article-title":"Tramadol: pain relief by an opioid without depression of respiration","volume":"47","author":"Vickers","year":"1992","journal-title":"Anaesthesia"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0376-8716(91)90081-9","article-title":"Abuse potential and pharmacological comparison of tramadol and morphine","volume":"27","author":"Preston","year":"1991","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003495-199346020-00008","article-title":"Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states","volume":"46","author":"Lee","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0036","unstructured":"Food and Drug Administration (FDA). Ultram. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020281s032s033lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0037","unstructured":"Food and Drug Administration (FDA). Conzip. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022370s015lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0038","unstructured":"Food and Drug Administration (FDA). Norco. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/040099s023lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0039","unstructured":"Food and Drug Administration (FDA). HYSINGLA ER. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206627s004lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0040","unstructured":"Food and Drug Administration (FDA). ZOHYDRO ER. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202880s009s010lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0041","unstructured":"Food and Drug Administration (FDA). Roxicodone. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021011s002lbl.pdf. Accessed November 5, 2023."},{"issue":"1 Pt 2","key":"10.1016\/j.amjmed.2023.10.022_bib0042","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1399-6576.1997.tb04633.x","article-title":"Pharmacokinetics and pharmacodynamics of controlled-release opioids","volume":"41","author":"Kaiko","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0043","unstructured":"Food and Drug Administration (FDA). Oxycontin. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020553s059lbl.pdf. Accessed November 5, 2023.Vol 2023."},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.022_bib0044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.1990.tb03638.x","article-title":"The metabolism and bioavailability of morphine in patients with severe liver cirrhosis","volume":"29","author":"Hasselstr\u00f6m","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.022_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1213\/00000539-198704000-00001","article-title":"Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects","volume":"66","author":"Mazoit","year":"1987","journal-title":"Anesth Analg"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0046","unstructured":"Food and Drug Administration (FDA). Morphine sulfate oral solution. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022195s006lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0047","unstructured":"Food and Drug Administration (FDA). Morphine sulfate tablets. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022207s010lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0048","unstructured":"Food and Drug Administration (FDA). MS Contin. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019516s049lbl.pdf. Accessed November 5, 2023."},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.022_bib0049","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0050","unstructured":"Food and Drug Administration (FDA). Dilaudid oral liquid and Dilaudid tablets. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019891s024,019892s029lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0051","unstructured":"Food and Drug Administration (FDA). Hydromorphone hydrochloride extended-release tablets. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202144s006lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0052","unstructured":"Food and Drug Administration (FDA). Fentanyl citrate injection. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/016619s034lbl.pdf. Accessed November 5, 2023."},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.022_bib0053","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/bja\/54.12.1267","article-title":"Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis","volume":"54","author":"Haberer","year":"1982","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0054","unstructured":"Food and Drug Administration (FDA). Duragesic. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/019813s081lbl.pdf. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0055","unstructured":"LiverTox. Gabapentin. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548252\/. Accessed November 5, 2023."},{"key":"10.1016\/j.amjmed.2023.10.022_bib0056","unstructured":"LiverTox. Pregabalin. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548053\/#top. Accessed November 5, 2023."},{"issue":"10","key":"10.1016\/j.amjmed.2023.10.022_bib0057","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.022_bib0058","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2021.12.013","article-title":"Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study","volume":"76","author":"Chalasani","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.amjmed.2023.10.022_bib0059","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/MEG.0b013e328300c978","article-title":"Pregabalin as a probable cause of acute liver injury","volume":"20","author":"Einarsdottir","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.022_bib0060","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.022_bib0061","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1365-2036.2010.04449.x","article-title":"Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network","volume":"32","author":"Vuppalanchi","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.022_bib0062","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/157488608784529198","article-title":"Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events","volume":"3","author":"Wernicke","year":"2008","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.amjmed.2023.10.022_bib0063","unstructured":"Food and Drug Administration (FDA). Cymbalta. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022516lbl.pdf. Accessed November 5, 2023. Vol 2023."},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.022_bib0064","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10133","article-title":"Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster","volume":"91","author":"Campbell","year":"2002","journal-title":"J Pharm Sci"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:32:09Z","timestamp":1757583129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323006721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0002934323006721"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.10.022","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}